Auranofin, an inhibitor of cathepsin B, and captopril, an ACE inhibitor, are included in the coordinated undermining of survival paths (CUSP9) treatment protocol—a trial targeting recurrent GB by combining nine repurposed drugs with temozolomide, highlighting the six themes important to cancer therapy, accepting that cytotoxic drugs alone are futile in prolonging survival of GB patients and these drugs may improve the efficacy of chemotherapeutic agents such as temozolomide [95]. This evidence concerns the gene ACE and cancer.